The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept.
In this case report, we present the first report of erythema elevatum diutinum after treatment of juvenile idiopathic arthritis with abatacept. Although it could also be coincidental, in our case, the appearance of vasculitis was not blocked by the simultaneous administration of a stimulation inhibitor, and alerts to the fact that as effective as a abatacept may be to control of the inflammatory articular symptoms, this might not translate into control of the disease.
Golmia
Andrea
A
Hospital Israelita Albert Einstein and Research Institute, Sao Paulo, Brazil.
Grinblat
Beni
B
Finger
Eduardo
E
Klieman
Claudia
C
Assir
Fernanda
F
Scheinberg
Morton
M
D000069594:Abatacept; D000287:Administration, Topical; D000293:Adolescent; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000150:complications / Q000188:drug therapy*; D004890:Erythema / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology
D018501:Antirheumatic Agents; D005938:Glucocorticoids; D018796:Immunoconjugates; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept